EirGenix - Asset Resilience Ratio

Latest as of December 2024: 4.60%

EirGenix (6589) has an Asset Resilience Ratio of 4.60% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$500.00 Million

≈ $15.75 Million USD Cash + Short-term Investments

Total Assets

NT$10.88 Billion

≈ $342.67 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how EirGenix's Asset Resilience Ratio has changed over time. Check how strategically is EirGenix's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down EirGenix's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 6589 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$500.00 Million	4.6%
Total Liquid Assets	NT$500.00 Million	4.60%

Asset Resilience Insights

Limited Liquidity: EirGenix maintains only 4.60% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

EirGenix Industry Peers by Asset Resilience Ratio

Compare EirGenix's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for EirGenix (2017–2024)

The table below shows the annual Asset Resilience Ratio data for EirGenix.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	4.60%	NT$500.00 Million ≈ $15.75 Million	NT$10.88 Billion ≈ $342.67 Million	+0.12pp
2023-12-31	4.48%	NT$500.00 Million ≈ $15.75 Million	NT$11.16 Billion ≈ $351.68 Million	-3.96pp
2022-12-31	8.44%	NT$1.00 Billion ≈ $31.51 Million	NT$11.85 Billion ≈ $373.25 Million	-6.11pp
2021-12-31	14.55%	NT$1.66 Billion ≈ $52.45 Million	NT$11.44 Billion ≈ $360.45 Million	+11.57pp
2020-12-31	2.99%	NT$114.52 Million ≈ $3.61 Million	NT$3.84 Billion ≈ $120.83 Million	-6.67pp
2017-12-31	9.65%	NT$163.64 Million ≈ $5.16 Million	NT$1.70 Billion ≈ $53.41 Million	--

pp = percentage points

About EirGenix

TWO:6589 Taiwan Biotechnology

Market Cap

$632.48 Million

NT$20.08 Billion TWD

Market Cap Rank

#10884 Global

#368 in Taiwan

Share Price

NT$66.40

Change (1 day)

+0.00%

52-Week Range

NT$66.40 - NT$66.40

All Time High

NT$188.50